Trial backs efficacy of Echo's continuous glucose monitor

12/3/2013 | (Boston)

Echo Therapeutics said its Symphony device, designed to monitor glucose levels continuously, achieved the main safety and efficacy goals of a clinical study meant to back the company's CE mark approval application for the product. The study found that 97.9% of the device's glucose readings were clinically accurate and that 1.8% were benign errors.

View Full Article in: (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX